Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLTi, Hepatic Glucose Production and Ketogenesis
Sponsor: The University of Texas Health Science Center at San Antonio
Summary
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. MAIN STUDY: To examine the effect of empagliflozin versus empagliflozin/pancreatic clamp on EGP (6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybuyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.
Official title: Protocol l: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-10-05
Completion Date
2027-06-30
Last Updated
2025-07-01
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 25 MG
A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Placebo
Inert tablet
Locations (1)
Texas Diabetes Institute/UH
San Antonio, Texas, United States